Natera’s Signatera Genome separates bladder cancer patients into 91%, 81% and 55% survival groups, but can MRD guide treatment?
Natera reports 91% two-year event-free survival in persistently ctDNA-negative VOLGA patients, strengthening MRD research in bladder cancer.